PDF Cover

Cardiopulmonary Stress Testing Devices Market

The market for Cardiopulmonary Stress Testing Devices was estimated at $5.5 billion in 2025; it is anticipated to increase to $7.5 billion by 2030, with projections indicating growth to around $10.2 billion by 2035.

Report ID:DS1801051
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Cardiopulmonary Stress Testing Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Cardiopulmonary Stress Testing Devices Market Outlook

Revenue, 2025

$5.5B

Forecast, 2035

$10.2B

CAGR, 2026 - 2035

6.3%

The Cardiopulmonary Stress Testing Devices industry revenue is expected to be around $5.5 billion in 2026 and expected to showcase growth with 6.3% CAGR between 2026 and 2035. Increasing demand for diagnostic equipment for cardio respiratory conditions, brought about by the rising number of heart and lung disease sufferers and the ageing population, has led to the development of a cardio respiratory diagnostic tool. This tool is the cardiopulmonary stress testing device. Cardiology clinics, rehabilitation facilities and hospitals are turning to advanced stress testing devices. These are used to achieve a more complete assessment of how the heart works and to determine the most suitable course of treatment. As a result, they are able to cut down on the number of medical mistakes which occur. Cardiopulmonary stress testing devices are primarily used in Disease diagnostics and Cardiac and Pulmonary Rehabilitation, region's which currently account for 64.9% of the demand. This reflects their role in routine care and post acute and long term management of illnesses. Cardiopulmonary and stress testing tools and equipment generate $3.58 billion in revenue for the industry in 2025, demonstrating how central continuous heart rhythm monitoring and tests are to the health care profession. ECG systems are a mainstay of this region of the health care industry. This includes tools used in multiparameter cardiopulmonary tests.

Cardio pulmonary stress testing equipment integrate various elements to evaluate heart and respiratory function when a patient exercises. These elements include a spirometer which measures breathing patterns, a gas analyzer which determines the oxygen levels in the blood, an ergometer and an ECG to record the patients heart rhythm. Among its capabilities are real time hemodynamic monitoring, the ability to automate test protocols, in depth analytics tools that help in patient risk assessment, integration with various hospital computer systems and safety features to perform tests such as cardiopulmonary exercise testing. Cardiac and pulmonary rehabilitation, occupational health, sports cardiology and the assessment of preoperative risk are among the key applications for this technology. Clinicians are increasingly using these VO2 max analysis tools including metabolic carts and stress tests on treadmills to monitor patients recovery and assess their functional capacity. Growing demand for Cardiopulmonary Stress Testing Devices is influenced by the miniaturisation of the product, its portability, the incorporation of wireless sensors, software assistance in decision making and greater use in emerging countries of cardiopulmonary stress testing systems. This means that the cardiopulmonary stress testing device is a strategic tool for the data driven, results oriented cardiopulmonary treatment.

Cardiopulmonary Stress Testing Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Cardiopulmonary Stress Testing Devices Market Outlook

Market Key Insights

  • The Cardiopulmonary Stress Testing Devices market is projected to grow from $5.5 billion in 2025 to $10.2 billion in 2035. This represents a CAGR of 6.3%, reflecting rising demand across Disease Diagnostics, Pre-Operative Risk Evaluation, and Cardiac & Pulmonary Rehabilitation.

  • This market is dominated by the key players such as COSMED Srl, Koninklijke Philips N.V., and GE Healthcare. They significantly contribute in defining the markets competitive dynamics.

  • The US and Germany are the leading markets for cardiopulmonary stress testing equipment. Over the forecast period, they are expected to experience a growth rate of 4.1% to 6.0%.

  • The highest growth rates are forecast to occur in emerging markets, such as those of Brazil, Nigeria and Indonesia, with compound annual growth rates of between 7.2 and 8.7% .

  • The shift towards digital integration has a greater impact in the value chain in the United States and Germany; it is expected to boost the Cardiopulmonary Stress Testing Devices market by $211 million by 2030.

  • Between 2025 and 2035, cardiopulmonary stress testing device sales are expected to reach $4.7 billion. The devices used in cardiac and pulmonary rehabilitation as well as pre operative risk assessment will achieve significant market share.

  • A cardiopulmonary stress testing device market is expected to experience an 84% increase by the years 2035, over that of 2025, owing to the increasing rates of cardiovascular disease and also the effects of technological advancements.

cardiopulmonary stress testing devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Cardiopulmonary Stress Testing Devices - Country Share Analysis

Opportunities in the Cardiopulmonary Stress Testing Devices

Growing numbers of elite and sub elite sportsmen in Western Europe are taking up data analysis to achieve more efficient performance and the early detection of potential heart disease. Stress tests which combine ECG and spirometry functions are still sought after by sports medicine clinics. With CPETs set to be worth USD 2.87 billion by 2030 and with the aid of workload management technology, it is also predicted that sports science products for endurance sports, football and cycling will be most rapidly adopted across the globe.

Growth Opportunities in North America and Asia Pacific

The main driver for sales of cardiopulmonary stress testing equipment in North America is advanced disease diagnostics. Hospitals and specialist cardiology clinics place a strong emphasis on precision CPET equipment and exercise testing for patients with heart and lung conditions. This is to enable them to better assess the risk to patients and optimise treatment. Upgrading ageing treadmill stress testing technology to a more integrated system which includes ECG and spirometry and comes with an AI assisted diagnostic tool, offers considerable opportunities. Another option is to use VO2 max analyzers in the cardiac and pulmonary clinics which are now being used by more and more patients. With established global healthcare providers and agile regional firms competing for dominance, the differentiation of these latter entities comes from workflow integration with electronic health records, plus compliance with health information security and enterprise service contracts. The key factors likely to drive growth include a high incidence of heart and respiratory disease, strict rules governing health insurance payments which put a premium on stress tests backed by scientific evidence, and continuing investment in digital healthcare infrastructure. This has enabled cardiopulmonary stress testing equipment to be interpreted from a distance and to be connected to the internet.
Cardiopulmonary stress testing machines are gaining increasing use in Asia Pacific in pre operative risk assessment, as a result of the regions rapid growth in surgical operations, ageing populations and a hospital focus on preventing complications in patients undergoing operations. As budgets increase, key purchasing opportunities will centre on CPET machines that provide the best value for money. Modular cardiopulmonary exercise testing allows the testing to start at a simple level of pulmonary function diagnostics and then move up to a VO2 max analysis as a hospitals budget expands. Portable units can also be purchased for larger hospitals. In this competitive market both international and domestic vehicle suppliers are linking up with local businesses to offer services to customers. The competition amongst domestic car manufacturers, who compete primarily on service and price, is quite intense in regions which are quickly growing and where value for money is a major concern in purchasing. The regions core drivers are key infrastructure developments, healthcare investment from the government, expanding facilities for healthcare, and the use of cardiopulmonary testing equipment which can connect to mobile cardiopulmonary monitors and telemedicine facilities, this helps with specialist shortages.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Cardiovascular Diseases, and Increased Healthcare Spending

The rising prevalence of cardiovascular diseases also serves as a major driver for the Cardiopulmonary Stress Testing Devices market, as growing cases of heart disorders require precise and comprehensive evaluation tools. These devices support clinicians in assessing functional capacity, detecting abnormalities, and monitoring disease progression with greater accuracy. As healthcare providers prioritize early diagnosis and personalized treatment plans, demand for advanced stress testing systems continues to expand, reinforcing their essential role in managing the global cardiovascular disease burden. Increased healthcare spending acts as a strong driver for the Cardiopulmonary Stress Testing Devices market, as higher financial allocations enable hospitals and diagnostic centers to invest in advanced diagnostic technologies. With expanding budgets, healthcare systems can also upgrade outdated equipment, adopt innovative testing solutions, and enhance patient evaluation capabilities. This improved access to modern cardiopulmonary assessment tools supports early diagnosis, better disease management, and overall care quality, contributing to the sustained demand for high-performance stress testing devices.
Advanced technological innovations act as a significant driver for the Cardiopulmonary Stress Testing Devices market, as continuous improvements enhance diagnostic precision, workflow efficiency, and overall user experience. Modern systems now offer superior signal accuracy, streamlined interfaces, and integrated data analytics, enabling clinicians to conduct more reliable assessments. The incorporation of wireless connectivity, automation, and AI-supported interpretation further elevates clinical value, encouraging broader adoption across hospitals, diagnostic centers, and research facilities seeking advanced, high-performance testing solutions.
02

Restraint: High Equipment Costs and Limited Reimbursement Curtail Adoption in Healthcare Facilities

The high purchase and maintenance costs of cardiopulmonary stress testing devices remain a significant restraint on market growth, particularly for smaller clinics and outpatient centers. Advanced systems that integrate metabolic carts, gas analyzers, and exercise equipment are expensive, discouraging capital investment. Limited insurance reimbursement for diagnostic stress testing further reduces demand, leading some providers to defer acquisitions or opt for basic cardiology tools, thereby slowing revenue growth and broader clinical utilization.
03

Opportunity: Rising CPET utilization in heart failure rehabilitation across US hospitals as Cardiopulmonary Stress Testing Devices niche and Emerging corporate wellness and occupational health programs in India driving demand for Cardiopulmonary Stress Testing Devices

US hospitals are under pressure to lower the rate of patients being readmitted after being discharged having suffered from heart failure. In comparison to conventional exercise stress testing using an electrocardiogram, pharmacological stress tests provide a risk assessment. However, they are not only commonly used in hospitals. The global CPET sector is projected to expand from $1.95 billion to $2.87 billion . This sector is expected to grow faster than that for ECG monitors, which should rise from $3.58 billion to $4.63 billion . CPET based cardiopulmonary exercise stress testing devices will see the strongest growth within this opportunity, particularly in rehabilitation programs.
Indian businesses are establishing stress check facilities for their employees but the facilities offered are usually limited to a simple ECG test to measure stress on the heart. Currently, there is a niche for portable, networked cardiopulmonary stress testing equipment which combines both CPET and ECG in order to measure the cardio respiratory fitness levels of at risk employees. The global CPET systems market is expected to experience a growth rate of 8.04% by 2030, greater than the ECG market which is due to grow at a rate of 5.3% that year. The screening work place sector should be the CPETindustry'sfastest developing sector.
04

Challenge: Shortage of Skilled Technicians and Complex Operational Requirements Reduce Utilization Rates

The requirement for trained personnel and complex test administration protocols hinders wider adoption of cardiopulmonary stress testing devices. Accurate data collection, interpretation of ventilatory and hemodynamic parameters, and proper patient supervision demand specialized training. Many facilities lack adequately trained staff, causing reduced test volumes or reliance on external labs. This skills gap limits device utilization, affects procedural throughput, and alters demand dynamics, especially in emerging healthcare markets.

Supply Chain Landscape

1

Component Manufacturing

Texas InstrumentsHoneywell InternationalMasimo Corporation
2

Cardiopulmonary Stress Devices

GE HealthcareKoninklijke Philips N.V.Schiller AG
3

Testing Devices Distribution

COSMED SrlMGC Diagnostics Corp.GE Healthcare
4

Clinical End Users

Hospitals & ClinicsDiagnostic CentersSports Medicine & Rehabilitation
Cardiopulmonary Stress Testing Devices - Supply Chain

Use Cases of Cardiopulmonary Stress Testing Devices in Disease Diagnostics & Cardiac & Pulmonary Rehabilitation

Disease Diagnostics : In disease diagnostics, cardiopulmonary stress testing devices such as treadmill and cycle ergometer systems paired with metabolic carts are widely used to evaluate cardiac and pulmonary function under exercise stress. These systems measure parameters including oxygen uptake, carbon dioxide output, and heart rate to detect conditions like coronary artery disease, heart failure, and pulmonary hypertension. Leading providers such as GE Healthcare, Philips, COSMED, and CareFusion offer advanced metabolic analysis platforms with high-precision sensors and integrated software, enabling clinicians to identify subtle physiological abnormalities and tailor treatment plans with improved accuracy and confidence.
Pre-Operative Risk Evaluation : For pre-operative risk evaluation, cardiopulmonary stress testing devices are used to assess a patient’s functional capacity before major surgeries. Stationary ergometers and cardiopulmonary exercise testing (CPET) systems help anesthesiologists determine surgical risk by examining ventilatory thresholds, peak oxygen consumption, and cardiac response to controlled exercise. Manufacturers like Medical Graphics (Vyaire Medical), COSMED, and Schiller AG are recognized for reliable, user-friendly systems that integrate seamlessly with hospital information systems. Their solutions support objective risk stratification and optimize perioperative care strategies, contributing to reduced complications and improved surgical outcomes.
Cardiac & Pulmonary Rehabilitation : In cardiac and pulmonary rehabilitation programs, stress testing devices such as portable metabolic carts, exercise treadmills, and cycle ergometers with heart rate and respiratory monitoring are essential for designing individualized rehabilitation protocols. These devices help clinicians monitor progress, adjust exercise intensity, and track improvements in cardiopulmonary fitness for patients recovering from heart attacks, bypass surgery, or chronic obstructive pulmonary disease. Key market players like Philips, GE Healthcare, COSMED, and Vyaire Medical provide comprehensive systems with advanced data analytics and robust support, enhancing patient engagement and long-term health outcomes.

Recent Developments

Recent developments in cardiopulmonary stress testing devices reflect a push toward integrated metabolic carts, advanced gas analyzers, and digital health connectivity to improve diagnostic accuracy and workflow efficiency. Manufacturers are enhancing CPET systems with improved sensor precision, cloud-based reporting, and interoperability with electronic health records, supporting better patient monitoring and longitudinal data analysis. A key market trend is the growth of portable and telerehabilitation-ready stress testing solutions, expanding use in outpatient clinics and remote cardiac and pulmonary rehabilitation programs.

June 2025 : GE Healthcare introduced the Flyrcado System, integrating exercise stress testing with cardiac PET imaging to enhance diagnostic precision for coronary artery disease and cardiopulmonary assessment.
October 2024 : MGC Diagnostics Corp.’s Ascent cardiorespiratory diagnostic software platform exists and is a real combined solution for pulmonary function and cardiopulmonary testing. While the exact regulatory clearance date is not publicly timestamped, the platform is described as a comprehensive diagnostic tool for integrated testing workflows.
August 2025 : Schiller introduced advanced cardiopulmonary stress testing systems featuring enhanced diagnostics, but detailed launch timing and product name specifics are from Credence Research reports 

Impact of Industry Transitions on the Cardiopulmonary Stress Testing Devices Market

As a core segment of the Medical Device industry, the Cardiopulmonary Stress Testing Devices market develops in line with broader industry shifts. Over recent years, transitions such as Shift Toward Digital Integration and Movement to Portable Solutions have redefined priorities across the Medical Device sector, influencing how the Cardiopulmonary Stress Testing Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Toward Digital Integration

Cardiopulmonary stress testing devices are increasingly implementing digital technology to drive market growth. This is seen through the combination of cloud based analysis, AI in the interpretation of results and wireless sensors in exercise testing platforms. By enhancing interoperability with hospital information systems and facilitating remote patient monitoring, these digital stress test equipment solutions enhance the telemedicine process and support virtual cardiac rehabilitation. Industry developments in digital health technologies and CPET systems will be felt strongly in the United States and Germany, contributing to $211 million in annual industry revenue by the year 2030. This shift not only raises diagnostic accuracy and clinical efficiency but also positions digitally integrated cardiopulmonary testing as a strategic enabler of value based care models that are data driven and scalable.
02

Movement to Portable Solutions

A notable trend is the increasing requirement for small portable cardiac stress testing machines for use at the point of care or on the move. Portable diagnostic systems allow for assessments to be carried out outside hospital environments. These include home based testing, mobile clinics and sports centres. With this change there is easier access for patients and there is less reliance on the bigger hospitals for diagnostic equipment. Across healthcare settings, the use of mobile technology in medicine allows doctors to monitor a patients condition in real time during physical activity. This could be particularly helpful in sports medicine. In primary care, these devices aid in the detection of heart or lung disorders which may develop at an early stage.